

Table S1. Multiple Regression Analysis of the effect of HLA-C matching score on the outcomes after dUCB transplantation in endpoints that there was an interaction with conventional HLA-matching at -A,-B, and -DRB1 (OS & NRM).

Match at	HLA 2-4/6			HLA 5-6/6		
	N	HR (95% CI)	P-value	N	HR (95% CI)	P-value
OVERALL SURVIVAL &						
HLA-C match worst						
2/2*	29	1.0 (ref)		48	1.0 (ref)	
1/2	241	2.6 (1.3-5.4)	0.01	70	0.8 (0.5-1.3)	0.37
0/2	119	3.1 (1.5-6.4)	<0.01	8	0.3 (0.3-2.9)	0.92
Worst HLA-A,-B and -DRB1 Match						
6/6*				24	1.0 (ref)	
5/6				102	1.1 (0.5-2.)	0.92
4/6*	256	1.0 (ref)				
3/6	106	1.1 (0.8-1.5)	0.67			
2/6	27	0.8 (0.5-1.4)	0.48			
Age						
<18	26	1.0 (ref)		21	1.0 (ref)	
18-34	77	1.6 (0.7-3.3)	0.24	20	0.5 (0.2-1.2)	0.10
35+	286	2.7 (1.3-5.5)	0.01	85	0.3 (0.1-0.7)	0.01
Disease Risk						
Standard risk*	227	1.0 (ref)		84	1.0 (ref)	
High risk	162	1.6 (1.2-2.1)	<0.01	42	1.1 (0.6-1.8)	0.81
Patient CMV						
Negative*	158	1.0 (ref)		NA		
Positive	231	1.7 (1.3-2.2)	<0.01	NA		
Non-Relapse Mortality £						
HLA-C match worst						
2/2*	29	1.0 (ref)		48	1.0 (ref)	
1/2	241	5.3 (1.3-22.1)	0.02	70	0.9 (0.4-2.0)	0.82
0/2	119	6.5 (1.5-27.2)	0.01	8	1.6 (0.3-7.8)	0.57
Worst HLA-A,-B and -DRB1 Match						
6/6*				24	1.0 (ref)	
5/6				102	1.2 (0.4-3.7)	0.76
4/6*	256	1.0 (ref)				
3/6	106	0.9 (0.6-1.4)	0.62			
2/6	27	0.9 (0.5-2.0)	0.87			
Age						
<18	26	1.0 (ref)		NS	NS	NS
18-34	77	1.6 (0.8-3.6)	0.22	NS	NS	NS

35+	286	2.0 (1.0-4.2)	0.06	NS	NS	NS
Disease Risk						
Standard risk*	227	1.0 (ref)		84	1.0 (ref)	
High risk	162	2.0 (1.4-2.8)	<0.01	42	1.6 (0.8-3.4)	0.20
Patient CMV						
Negative*	158	1.0 (ref)		NS	NS	NS
Positive	231	1.6 (1.1-2.3)	0.02	NS	NS	NS
Conditioning						
MA*	123	1.0 (ref)		54	1.0 (ref)	
RIC	266	0.3 (0.2-0.5)	<0.01	72	0.4 (0.2-0.9)	0.02

HLA, human leukocyte antigen; dUCB, double umbilical cord blood; N, number of patients; CI, confidence interval; CMV, cytomegalovirus; MA, myeloablative conditioning; RIC, reduced intensity conditioning; GVHD, graft-vs-host disease.

* Reference group

& Overall survival and disease-free survival among 4/6 + 4-6/6 were stratified by transplant center and intensity of the conditioning regimen, while for 5/6+-5-6/6 were stratified by transplant center

£ Stratified by transplant center

Table S2. Multivariate analysis of the effect of HLA-C after dUCB transplantation in endpoints that there was NO interaction with conventional HLA-matching at –A,-B, and -DRB1 (Relapse).

	N	HR (95% Confidence interval)	P-value
RELAPSE £			
HLA-C match worst			
2/2*	77	1.0 (ref)	
1/2	311	0.8 (0.5-1.3)	0.37
0/2	127	0.9 (0.5-1.6)	0.77
Worst HLA Match –A, -B, and –DRB1			
6/6*	24	1.0	
5/6	102	0.5 (0.3-1.1)	0.09
4/6	256	0.6 (0.3-1.2)	0.14
3/6	106	0.6 (0.3-1.2)	0.17
2/6	27	0.5 (0.2-1.5)	0.22
Disease Risk			
Standard risk*	311	1.0	
High risk	204	1.1 (0.8-1.5)	0.70
Conditioning			
MA *	166	1.0	
RIC	349	2.9 (1.8-4.5)	<0.01
Grade II-IV aGVHD			
No*	305	1.0	
Yes	210	0.6 (0.4-0.9)	0.01

HLA, human leukocyte antigen; dUCB, double umbilical cord blood; N, number of patients; CI, confidence interval; MA, myeloablative conditioning; RIC, reduced intensity conditioning; GVHD, graft-vs-host disease.

* Reference group

£ Stratified by transplant center